Health Care • Biotechnology: Pharmaceutical Preparations
$1.17 ▼ -0.06
(-4.88%)
MKT CAP: $35.6M • VOL: 341.1K
52W L $1 52W H $2
LITS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $65.3M | $48.8M |
| YoY Revenue Growth % | — | +33.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.5M | $14.5M | -$36.8M |
| Operating Margin % | — | 22.3% | -75.3% |
| Net Income (GAAP) | -$15.9M | $18.0M | -$32.0M |
| EBITDA (Normalized) | -$17.5M | $14.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$20.8M | -$50.5M | -$52.5M |
| Capital Expenditures (CapEx) | $0 | $7.0K | — |
| Free Cash Flow (FCF) | -$20.8M | -$50.5M | -$52.5M |
| FCF Margin % | — | -77.3% | -80.0% |
| Return on Invested Capital (ROIC %) | -18.9% | 95.0% | — |
| Cash & Short-Term Equivalents | $8.8M | $23.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $81.8M | $22.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LITS.